We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Breath-Based Biomarkers Identified for Tuberculosis Diagnosis

By LabMedica International staff writers
Posted on 19 Dec 2022

Tuberculosis (TB) remains one of the top ten causes of death worldwide and is the leading cause of death from a single infectious agent. More...

About a quarter of the world’s population is infected with Mycobacterium tuberculosis (Mtb), and thus at risk of developing TB.

Most conventional diagnostic tests rely on sputum samples, which can be difficult to obtain and have low diagnostic sensitivity in children, HIV-infected individuals and patients with extrapulmonary TB. Therefore, the ideal diagnostic would not rely on sputum samples, and can also detect non-pulmonary TB.

Medical Scientists at the University of Toulouse III-Paul Sabatier (Toulouse, France) and their numerous colleagues included in a study eight patients between 27 and 62 years old, diagnosed with pulmonary TB by direct Ziehl-Neelsen staining and culture of sputum; 21 patients with at least three sputum samples negative for Ziehl-Neelsen staining; children (aged 6–12) were separated into two groups based on the detection or not of mycobacteria; 15 adults (aged 18–61) who presented with community-acquired pneumonia and 15 healthy adult individuals. With the goal of developing a non-sputum-based TB diagnostic, the team examined whether pulmonary TB could be detected in exhaled breath condensate (EBC) samples.

The EBCs were collected using R-tubes (Respiratory Research, Inc, Austin, TX, USA). EBCs were lyophilized and adjusted to a volume of 250 µL of LPS-free water. EBCs were spotted using the Bio-Dot SF blotting apparatus (Bio-Rad, Hercules, CA, USA) and used for Dot-blot immunoassays. The scientists then performed monosaccharide analysis and quantification by capillary electrophoresis monitored by laser-induced fluorescence (CE-LIF). MALDI-TOF analyses were performed on an AB Sciex TOF/TOF 5800 mass spectrometer using the reflectron mode (Framingham, MA, USA).

The investigators reported that that the presence of M. tuberculosis-specific lipids, lipoarabinomannan lipoglycan, and proteins in EBCs can efficiently differentiate baseline TB patients from controls. They used EBCs to track the longitudinal effects of antibiotic treatment in pediatric TB patients. In addition, M. tuberculosis lipoarabinomannan and lipids were structurally distinct in EBCs compared to ex vivo cultured bacteria, revealing specific metabolic and biochemical states of M. tuberculosis in the human lung.

The authors concluded that sampling exhaled air is non-invasive and appears to be a powerful approach that overcomes the limitations in existing assays. An EBC-based approach therefore has potentially broad application for following other pulmonary infectious agents. The study was published on December 14, 2022 in the journal Nature Communications.

Related Links:
University of Toulouse III-Paul Sabatier
Respiratory Research
Bio-Rad
AB Sciex


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.